Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy.
5-miRNAs
GO and KEGG enrichment analyses
breast cancer
drug resistance
neoadjuvant chemotherapy
nomogram model
serum microRNAs
Journal
Breast cancer (Dove Medical Press)
ISSN: 1179-1314
Titre abrégé: Breast Cancer (Dove Med Press)
Pays: New Zealand
ID NLM: 101591856
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
03
2023
accepted:
22
07
2023
medline:
18
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
The effect of chemotherapy in patients with breast cancer (BC) is uncertain. This study attempted to analyze serum microRNAs (miRNAs) in NAC resistant and sensitive BC patients and develop a miRNA-based nomogram model. To further help clinicians make treatment decisions for hormone receptor-positive patients. A total of 110 BC patients with NAC were recruited and assigned in sensitive and resistant group, and 4 sensitive patients and 3 resistant patients were subjected to high-throughput sequencing. The functions of their target genes were analyzed by GO and KEGG. Five BC-related reported miRNAs were selected for expression pattern measurement by RT-qPCR and multivariate logistic analysis. The nomogram model was developed using R 4.0.1, and its predictive efficacy, consistency and clinical application value in development and validation groups were evaluated using ROC, calibration and decision curves. There were 44 differentially-expressed miRNAs in resistant BC patients. miR-3646, miR-4741, miR-6730-3p, miR-6831-5p and miR-8485 were candidate for resistance diagnosis in BC. Logistic multiple regression analysis showed that miR-4741 (or = 0.30, 95% CI = 0.08-0.63, P = 0.02) and miR-6831-5p (or = 0.48, 95% CI = 0.24-0.78, P = 0.01) were protective factors of BC resistance. The ROC curves showed a sensitivity of 0.884 and 0.750 for miR-4741 and miR-6831-5P as markers of resistance, suggesting that they can be used as independent risk factors for BC resistance. The other 3 miRNAs can be used as calibration factors to establish the risk prediction model of resistance in BC. In risk model, the prediction accuracy of resistance of BC is about 78%. 5-miRNA signature diagnostic models can help clinicians provide personalized treatment for NAC resistance BC patients to improve patient survival. MiR-4741 and miR-6831-5p are independent risk factors for breast cancer resistance. This study constructed a nomogram model of NAC resistance in BC based on 5 differentially-expressed serum miRNAs.
Identifiants
pubmed: 37593370
doi: 10.2147/BCTT.S415080
pii: 415080
pmc: PMC10427486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
591-604Informations de copyright
© 2023 Fan et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
Int J Oncol. 2015 Sep;47(3):840-8
pubmed: 26202679
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638377
Front Genet. 2018 May 18;9:174
pubmed: 29868122
Cell Death Dis. 2021 Nov 16;12(12):1088
pubmed: 34789738
Front Genet. 2022 Jun 30;13:865472
pubmed: 35846122
J Hematol Oncol. 2018 May 30;11(1):72
pubmed: 29848346
Cancer Sci. 2019 Jan;110(1):408-419
pubmed: 30382619
PLoS One. 2022 May 26;17(5):e0268300
pubmed: 35617163
Sci Rep. 2021 May 31;11(1):11348
pubmed: 34059778
Front Oncol. 2022 May 12;12:899145
pubmed: 35664800
Int J Mol Sci. 2021 Oct 06;22(19):
pubmed: 34639152
Cancers (Basel). 2019 Mar 11;11(3):
pubmed: 30862050
Clin Cancer Res. 2007 Apr 1;13(7):2199-206
pubmed: 17404104
Updates Surg. 2017 Sep;69(3):313-317
pubmed: 28260181
Cancer Manag Res. 2018 Oct 23;10:4747-4757
pubmed: 30425571
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg Oncol. 2015 May;22(5):1408-15
pubmed: 25727557
PLoS One. 2016 Apr 05;11(4):e0153194
pubmed: 27045586
J Lab Autom. 2015 Oct;20(5):574-88
pubmed: 25524488
Life Sci. 2021 Apr 15;271:119110
pubmed: 33513401
Biomed Pharmacother. 2018 Nov;107:117-128
pubmed: 30086458
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207
pubmed: 29074454
Front Genet. 2022 Mar 21;13:838869
pubmed: 35386284
Evid Based Complement Alternat Med. 2022 May 23;2022:1375724
pubmed: 35656462
J Exp Clin Cancer Res. 2012 May 03;31:42
pubmed: 22553917
Oxid Med Cell Longev. 2019 Aug 8;2019:5357649
pubmed: 31485295
Cancers (Basel). 2015 Oct 26;7(4):2147-68
pubmed: 26516917
Clin Chim Acta. 2012 Jul 11;413(13-14):1058-65
pubmed: 22387599
Cancer Sci. 2016 Mar;107(3):326-34
pubmed: 26749252
Oncol Rep. 2020 Jan;43(1):240-250
pubmed: 31746410
Clin Rheumatol. 2021 Jan;40(1):331-339
pubmed: 32533339
Sci Rep. 2017 Mar 22;7:44673
pubmed: 28327615
Breast Cancer Res Treat. 2019 Jul;176(2):291-301
pubmed: 31006103
Ann N Y Acad Sci. 2005 Nov;1059:56-60
pubmed: 16382043
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S
pubmed: 26834110
Front Immunol. 2021 Oct 26;12:734745
pubmed: 34764953
Nat Commun. 2016 Apr 13;7:11245
pubmed: 27071537
Curr Oncol. 2015 Apr;22(2):97-104
pubmed: 25908908
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244548